Nearly two years after the company filed its new drug application, Orphan Medical Inc. said after the markets closed Wednesday it won FDA approval for Xyrem, designed to treat cataplexy associated with narcolepsy. (BioWorld Today)

Nearly two years after the company filed its new drug application, Orphan Medical Inc. said after the markets closed Wednesday it won FDA approval for Xyrem, designed to treat cataplexy associated with narcolepsy. (BioWorld Today)